Swedish Match North Europe AB

MATFORS, Sweden, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics AB (“NorthX”) is proud to announce the official inauguration of its state-of-the-art Innovation Hub at the Matfors facility. This significant milestone marks a major step forward in NorthX's commitment to the field of advanced therapies in Sweden. The Innovation Hub, co-funded by the Swedish Government, is poised to enhance the country's infrastructure for cutting-edge therapies and accelerate innovation in the biopharmaceutical sector. The Innovation Hub represents NorthX's dedication to pushing the boundaries of biotechnology by fostering collaboration, research, and development in advanced therapies. With a focus on manufacturing of advanced biologics including Vaccine, Cell and Gene therapies, the Innovation Hub is set to become a catalyst for breakthroughs in medical science. This facility supplements NorthX's existing expertise in Plasmid and Protein manufacturing by adding mRNA services, reinforcing the company's position as a comprehensive solution provider in the biopharmaceutical industry. NorthX has experienced rapid growth, expanding its portfolio to encompass a wide range of services that cater to the evolving needs of the industry. The addition of the Matfors Innovation Hub, combined with the recent acquisition of a site in Stockholm, with state-of-the-art facilities and expertise for GMP biomanufacturing through mammalian cell culture processes, further solidifies NorthX's commitment to advancing life-changing therapies. "We are thrilled to unveil the Innovation Hub at our Matfors facility and it represents our dedication to driving innovation and progress in the field of biopharmaceuticals," said Janet Hoogstraate, CEO of NorthX Biologics AB. "This hub stands as a testament to the collaborative efforts of NorthX and the Swedish Government, as well as our ongoing commitment to providing cutting-edge solutions to our partners and clients for bringing new therapies to patients." NorthX Biologics AB extends its gratitude to all stakeholders, partners, and employees who have contributed to the realization of the Innovation Hub. The facility represents a shared vision of advancing science and medicine to improve the lives of patients worldwide. For more information, please contact: Janet Hoogstraate, CEO – janet.hoogstraate@nxbio.com About NorthX Biologics AB: NorthX Biologics, a leading Nordic Development and Manufacturing Organization, has expertise in producing cell and gene therapies, proteins, vaccines, other advanced biologics. With two sites in Sweden and headquartered in Matfors, the team has been manufacturing biologics to GMP standards since 1992. In 2021 NorthX was designated a national innovation hub for advanced therapies and vaccines and has the ambition to become a leading cell and gene therapy manufacturer and partner for innovative drug development companies. For more information see www.nxbio.com.

LUND, SWEDEN / ACCESSWIRE / July 25, 2022 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The rights issue in Spago Nanomedical AB (publ) is now registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") was Friday, July 22, 2022. The record date will be Tuesday, July 26, 2022, after which the BTAs are converted into ordinary shares on Thursday, July 28, 2022. For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se. Attachments The rights issue in Spago Nanomedical is registered SOURCE: Spago Nanomedical View source version on accesswire.com:

On May 21, 2021, the subscription period ended in Serstech AB´s (“Serstech”) rights issue. The rights issue was subscribed for a total of approx. SEK 26.9 million (excl. underwriting commitments), corresponding to a subscription rate of approx. 110 percent. Through the rights issue, a total of 12,572,412 shares will be issued and Serstech will be provided approx. SEK 24.5 million before issue costs. Settlement notes are expected to be sent out on May 26, 2021. Subscription and allotment in the rights issue The rights issue was subscribed to 26,878,004.40 SEK excluding underwriting commitments, corresponding to a subscription rate of approximately 110 percent. 12,572,412 new shares are issued and Serstech is thus provided approximately SEK 24.5 million before issue costs, which are estimated to amount to approximately SEK 2.25 million. 10,749,099 shares, corresponding to approximately 85.5 percent of the subscribed issue volume, are subscribed by shareholders with the support of subscription rights. Due to the high subscription rate, underwriting commitments are not activated. Settlement notes are expected to be sent out on May 26, 2021. Subscribers who are not allocated shares will not receive settlement notes. Number of shares and share capital When the rights issue has been registered with the Swedish Companies Registration Office, the number of shares in Serstech will amount to 83,816,085 shares and the share capital will amount to SEK 9,429,309. Trading in BTA (Paid-up for shares) Trading in BTA will take place on Nasdaq First North Growth Market until the Swedish Companies Registration Office has registered the rights issue. This registration is expected to take place in the beginning of June 2021. For further information, please contact: Stefan Sandor, CEO, Serstech AB Phone: +46 739 606067 Email: ss@serstech.com Thomas Pileby, Chairman of the Board, Serstech AB Phone: +46 702 072643 Email: tp@serstech.com or visit:  This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above at 8:00 CET on May 26, 2021. Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG), phone: +46 11 323 07 32, e-mail: ca@skmg.se. About Serstech Serstech delivers solutions for chemical identification and has customers around the world, mainly in the safety and security industry. Typical customers are customs, police authorities, security organizations and first responders. The solutions and technology are however not limited to security applications and potentially any industry using chemicals of some kind could be addressed by Serstech’s solution. Serstech’s head office is in Sweden and all production is done in Sweden. Serstech is traded at Nasdaq First North Growth Market and more information about the company can be found at .